An AstraZeneca Pharmaceuticals PLC subsidiary faces a lawsuit from a former director who said she was subjected to sexist treatment from male colleagues and retaliation after filing a report with HR ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Shares of AstraZeneca PLC AZN slid 1.78% to £105.12 Tuesday, on what proved to be an all-around dismal trading session for ...

Updated results from the OlympiA Phase 3 trial showed AstraZeneca (AZN) and Merck’s (MRK) Lynparza demonstrated sustained, clinically ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

AstraZeneca on Wednesday named Iskra Reic as its new international executive vice president (EVP), taking over from Leon Wang ...

Shares of AstraZeneca PLC AZN inched up 0.45% to £107.02 Monday, on what proved to be an all-around favorable trading session ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...